Study of Magrolimab in Patients With Solid Tumors | NCT04827576

ID	Type	Description	Link
2020-005265-14	EudraCT Number

Label	Type	Description	Intervention Names
Safety Run-in Cohort 1 (Magrolimab + Docetaxel)	Experimental	Participants with solid tumors (including metastatic non small cell lung cancer (mNSCLC), metastatic urothelial cancer (mUC), and metastatic small cell lung cancer (mSCLC)) will receive 1 mg/kg magrolimab intravenously (IV) on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 113 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 113 weeks; each cycle length = 21 days.	Drug: Magrolimab Drug: Docetaxel
Phase 2 Cohort 1a, mNSCLC (Magrolimab + Docetaxel)	Experimental	Participants with mNSCLC will receive 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 90 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 69 weeks; each cycle length = 21 days.	Drug: Magrolimab Drug: Docetaxel
Phase 2 Cohort 1b, mUC (Magrolimab + Docetaxel)	Experimental	Participants with mUC will receive 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 68 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 68 weeks; each cycle length = 21 days.	Drug: Magrolimab Drug: Docetaxel
Phase 2 Cohort 1c, mSCLC (Magrolimab + Docetaxel)	Experimental

Name	Type	Description	Arm Group Labels	Other Names
Magrolimab	Drug	Administered intravenously	Phase 2 Cohort 1a, mNSCLC (Magrolimab + Docetaxel) Phase 2 Cohort 1b, mUC (Magrolimab + Docetaxel) Phase 2 Cohort 1c, mSCLC (Magrolimab + Docetaxel)

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)	TEAEs were defined as any adverse events (AE) not present prior to the study treatment, or any events already present but worsening in either intensity or frequency following exposure to the study treatment. The TEAE reporting period is defined as the period from the date of the first dose of study treatment up to 30 days after the date of the last dose of study treatment or the day before initiation of subsequent antineoplastic therapy, whichever comes first. An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution.	First dose date up to 113 weeks plus 30 days
Percentage of Participants With Treatment-Emergent Laboratory Abnormalities	Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days and prior to the day of initiation of subsequent anti-cancer therapy. Percentages were rounded off.	First dose date up to 113 weeks plus 30 days
Objective Response Rate (ORR) (Phase 2 Cohorts 1a, 1b, and 1c)	ORR was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR), as measured by RECIST version 1.1, as determined by investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Clopper-Pearson method was used in outcome measure analysis. Percentages were rounded-off.	Up to 90 Weeks

Secondary Outcomes

Measure	Description	Time Frame
Progression-free Survival (PFS) (Phase 2 Cohorts 1a, 1b, and 1c)	PFS was defined as the interval from the first dosing date of any study drug to the earlier date of the first documentation of objective disease progression (PD) by investigator assessment per RECIST, Version 1.1, or death from any cause. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (the appearance of one or more new lesions was also considered progression). Kaplan-Meier (KM) estimates were used in outcome measure analysis.

Eligibility Module

Eligibility Criteria

Key Inclusion Criteria:

Individual must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
Adequate blood counts.
Adequate renal function.
Adequate liver function.
Pretreatment blood cross-match completed.
Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
Measurable disease according to response evaluation criteria in solid tumours (RECIST) version 1.1

Cohort-Specific Inclusion Criteria:

Safety Run-in Cohort 1: Individuals with metastatic advanced solid tumors who have had at least 1 prior line of systemic anticancer therapy (metastatic non-small cell lung cancer (mNSCLC) and metastatic small cell lung cancer (mSCLC)) in a locally advanced/metastatic setting, or 2 prior lines of systemic anticancer therapy (metastatic urothelial cancer (mUC)) in a locally advanced/metastatic setting, and not more than 3 prior lines of systemic anticancer therapy in a locally advanced/metastatic setting.
Phase 2 Cohort 1a (mNSCLC): Individuals with NSCLC who have had treatment with platinum-based chemotherapy and immune checkpoint inhibitor therapy in a locally advanced/metastatic setting, either in combination or sequentially (unless not eligible for one of these therapies) are eligible. At least 1 prior line of systemic anticancer therapy in a locally advanced/metastatic setting is required and not more than 2 prior lines of systemic anticancer therapy in a locally advanced/metastatic setting are allowed. Individuals treated with a taxane within 12 months or individuals refractory to prior taxane treatment are excluded. Individuals whose tumors have genomic alterations are excluded.
Phase 2 Cohort 1b (mUC): Individuals with UC who have had prior treatment with systemic chemotherapy and immune checkpoint inhibitor therapy in a locally advanced/metastatic setting (unless not eligible for one of these therapies) are eligible. At least 2 prior lines of systemic anticancer therapy in a locally advanced/metastatic setting are required and not more than 3 prior lines of systemic anticancer therapy in a locally advanced/metastatic setting are allowed. Individuals treated with a taxane within 12 months or individuals refractory to prior taxane treatment are excluded.
Phase 2 Cohort 1c (mSCLC): Individuals with SCLC who have had prior treatment with platinum-based chemotherapy and/or immune checkpoint inhibitor therapy are eligible. At least 1 prior line of systemic anticancer therapy in a locally advanced/metastatic setting is required and not more than 2 prior lines of systemic anticancer therapy in a locally advanced/metastatic setting are allowed. Individuals treated with a taxane within 12 months or individuals refractory to prior taxane treatment are excluded.

Note: Maintenance therapies are not counted as separate lines of therapy.

Key Exclusion Criteria:

Positive serum pregnancy test.
Breastfeeding female.
Active central nervous system (CNS) disease. Individuals with asymptomatic and stable, treated CNS lesions (radiation and/or surgery and/or other CNS-directed therapy who have not received corticosteroids for at least 4 weeks) are allowed.
Red blood cell (RBC) transfusion dependence, defined as requiring more than 2 units of packed red blood cell transfusions during the 4-week period prior to screening. RBC transfusions are permitted during the screening period and prior to enrollment to meet the hemoglobin inclusion criteria.
History of hemolytic anemia, autoimmune thrombocytopenia, or Evans syndrome in the last 3 months.
Known hypersensitivity to any of the study drugs, the metabolites, or formulation excipient.
Prior treatment with cluster of differentiation (CD)47 or signal regulatory protein alpha-targeting agents.
Current participation in another interventional clinical study.
Known inherited or acquired bleeding disorders.
Significant disease or medical conditions, as assessed by the investigator and sponsor, that would substantially increase the risk-benefit ratio of participating in the study. This includes, but is not limited to, acute myocardial infarction within the last 6 months, unstable angina, uncontrolled diabetes mellitus, significant active infections, and congestive heart failure New York Heart Association Class III-IV.
Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancies for which individuals are not on active anticancer therapies and who are in complete remission for over 3 years.
Known active or chronic hepatitis B or C infection or human immunodeficiency virus.
Prior anticancer therapy including but not limited to chemotherapy, immunotherapy, or investigational agents within 4 weeks prior to magrolimab is not permitted.
- Note: Localized non-CNS radiotherapy, previous hormonal therapy with luteinizing hormone releasing hormone agonists for prostate or breast cancer, and treatment with bisphosphonates and receptor activator of nuclear factor kappa B ligand (RANKL) inhibitors are not criteria for exclusion.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Name	Affiliation	Role
Gilead Study Director	Gilead Sciences	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Cancer Treatment Centers of America		Goodyear	Arizona	85338	United States
UC San Diego Moores Cancer Center

Label	URL
Gilead Clinical Trials Website	View source

ID	Title	Description
FG000	Safety Run-in Cohort 1 (Magrolimab + Docetaxel)	Participants with mSCLC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 72 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 72 weeks; each cycle length = 21 days.

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot	Yes	No	No	Study Protocol	Oct 24, 2023	Mar 24, 2025

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

TEAEs were defined as any adverse events (AE) not present prior to the study treatment, or any events already present but worsening in either intensity or frequency following exposure to the study treatment. The TEAE reporting period is defined as the period from the date of the first dose of study treatment up to 30 days after the date of the last dose of study treatment or the day before initiation of subsequent antineoplastic therapy, whichever comes first. An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution.

Participants in the Safety Analysis Set were analyzed. The Safety Analysis Set included all participants who took at least 1 dose of any study drug.

Posted

Number

percentage of participants

First dose date up to 113 weeks plus 30 days

ID	Title	Description
OG000	Safety Run-in Cohort 1 (Magrolimab + Docetaxel)	Participants with solid tumors (including metastatic non small cell lung cancer (mNSCLC), metastatic urothelial cancer (mUC), and metastatic small cell lung cancer (mSCLC)) received 1 mg/kg magrolimab intravenously (IV) on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 113 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 113 weeks; each cycle length = 21 days.
OG001	Phase 2 Cohort 1a, mNSCLC (Magrolimab + Docetaxel)	Participants with mNSCLC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 90 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 69 weeks; each cycle length = 21 days.
OG002	Phase 2 Cohort 1b, mUC (Magrolimab + Docetaxel)	Participants with mUC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 68 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 68 weeks; each cycle length = 21 days.
OG003	Phase 2 Cohort 1c, mSCLC (Magrolimab + Docetaxel)	Participants with mSCLC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 72 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 72 weeks; each cycle length = 21 days.

Units	Counts
Participants	OG0009 OG00129 OG00226 OG003

Title

Denominators

Categories

Title	Measurements
	OG000100.0 OG001100.0 OG002100.0 OG003

Primary

Percentage of Participants With Treatment-Emergent Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days and prior to the day of initiation of subsequent anti-cancer therapy. Percentages were rounded off.

Participants in the Safety Analysis Set were analyzed.

Posted

Number

percentage of participants

First dose date up to 113 weeks plus 30 days

ID	Title	Description
OG000	Safety Run-in Cohort 1 (Magrolimab + Docetaxel)	Participants with solid tumors (including metastatic non small cell lung cancer (mNSCLC), metastatic urothelial cancer (mUC), and metastatic small cell lung cancer (mSCLC)) received 1 mg/kg magrolimab intravenously (IV) on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 113 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 113 weeks; each cycle length = 21 days.
OG001	Phase 2 Cohort 1a, mNSCLC (Magrolimab + Docetaxel)	Participants with mNSCLC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 90 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 69 weeks; each cycle length = 21 days.

Primary

Objective Response Rate (ORR) (Phase 2 Cohorts 1a, 1b, and 1c)

ORR was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR), as measured by RECIST version 1.1, as determined by investigator assessment. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Clopper-Pearson method was used in outcome measure analysis. Percentages were rounded-off.

Participants in the modified intent to treat analysis set were analyzed. The study had 2 parts - Safety Run-in and Phase 2. Per pre-specified analysis, this endpoint was applicable only to Phase 2 cohorts. Therefore, data for cohorts of Phase 2 are reported.

Posted

Number

95% Confidence Interval

percentage of participants

Up to 90 Weeks

ID	Title	Description
OG000	Phase 2 Cohort 1a, mNSCLC (Magrolimab + Docetaxel)	Participants with mNSCLC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 90 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 69 weeks; each cycle length = 21 days.
OG001	Phase 2 Cohort 1b, mUC (Magrolimab + Docetaxel)	Participants with mUC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 68 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 68 weeks; each cycle length = 21 days.

Secondary

Progression-free Survival (PFS) (Phase 2 Cohorts 1a, 1b, and 1c)

PFS was defined as the interval from the first dosing date of any study drug to the earlier date of the first documentation of objective disease progression (PD) by investigator assessment per RECIST, Version 1.1, or death from any cause. PD is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (the appearance of one or more new lesions was also considered progression). Kaplan-Meier (KM) estimates were used in outcome measure analysis.

Participants in the modified Intent-to-Treat Analysis Set were analyzed. The study had 2 parts - Safety Run-in and Phase 2. Per pre-specified analysis, this endpoint was applicable only to Phase 2 cohorts. Therefore, data for cohorts of Phase 2 are reported.

Posted

Median

95% Confidence Interval

months

Up to 117 Weeks

ID	Title	Description
OG000	Phase 2 Cohort 1a, mNSCLC (Magrolimab + Docetaxel)	Participants with mNSCLC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 90 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 69 weeks; each cycle length = 21 days.
OG001	Phase 2 Cohort 1b, mUC (Magrolimab + Docetaxel)

Secondary

Duration of Response (DOR) (Phase 2 Cohorts 1a, 1b, and 1c)

DOR was defined as time from first documentation of CR or PR to the earliest date of documented PD, per RECIST, Version 1.1, or death from any cause, whichever occurs first, as determined by investigator assessment. CR and PR are defined in outcome measure #3 and PD is defined in outcome measure #4. KM Estimates were used in outcome measure analysis.

Participants in the modified Intent-to-Treat Analysis Set who achieved CR or PR were analyzed. The study had 2 parts - Safety Run-in and Phase 2. Per pre-specified analysis, this endpoint was applicable only to Phase 2 cohorts. Therefore, data for cohorts of Phase 2 are reported.

Posted

Median

95% Confidence Interval

months

Up to 117 Weeks

ID	Title	Description
OG000	Phase 2 Cohort 1a, mNSCLC (Magrolimab + Docetaxel)	Participants with mNSCLC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 90 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 69 weeks; each cycle length = 21 days.
OG001	Phase 2 Cohort 1b, mUC (Magrolimab + Docetaxel)	Participants with mUC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 68 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 68 weeks; each cycle length = 21 days.

Secondary

Overall Survival (OS) (Phase 2 Cohorts 1a, 1b, and 1c)

OS is defined as time from date of dose initiation to death from any cause. KM estimates were used in outcome measure analysis.

Posted

Median

95% Confidence Interval

months

Up to 117 Weeks

ID	Title	Description
OG000	Phase 2 Cohort 1a, mNSCLC (Magrolimab + Docetaxel)	Participants with mNSCLC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 90 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 69 weeks; each cycle length = 21 days.
OG001	Phase 2 Cohort 1b, mUC (Magrolimab + Docetaxel)	Participants with mUC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 68 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 68 weeks; each cycle length = 21 days.
OG002	Phase 2 Cohort 1c, mSCLC (Magrolimab + Docetaxel)

Secondary

Serum Concentration of Magrolimab

The participants in the Pharmacokinetic (PK) Analysis Set with available data were analyzed. The PK Analysis Set included all participants who received any amount of magrolimab and have at least 1 measurable posttreatment serum concentration of magrolimab. Here 'N' is defined as participants with available data at the given timepoint.

Posted

Mean

Standard Deviation

μg/mL

Day 1, Day 8 Predose, Day 8 1-Hour Postdose, Day 22, Day 43 Predose, Day 43 1-Hour Postdose, Day 85, Day 127, Day 190 and Day 253 Predose

ID	Title	Description
OG000	Safety Run-in Cohort 1 (Magrolimab + Docetaxel)	Participants with solid tumors (including metastatic non small cell lung cancer (mNSCLC), metastatic urothelial cancer (mUC), and metastatic small cell lung cancer (mSCLC)) received 1 mg/kg magrolimab intravenously (IV) on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 113 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 113 weeks; each cycle length = 21 days.
OG001	Phase 2 Cohort 1a, mNSCLC (Magrolimab + Docetaxel)	Participants with mNSCLC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 90 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 69 weeks; each cycle length = 21 days.

Secondary

Percentage of Participants Who Developed Anti-Magrolimab Antibodies

Participants in the Immunogenicity Analysis Set with available data were analyzed. The Immunogenicity Analysis Set includes all participants who received any amount of magrolimab and have at least 1 evaluable anti-magrolimab antibody test result.

Posted

Number

percentage of participants

Up to 113 Weeks

ID	Title	Description
OG000	Safety Run-in Cohort 1 (Magrolimab + Docetaxel)	Participants with solid tumors (including metastatic non small cell lung cancer (mNSCLC), metastatic urothelial cancer (mUC), and metastatic small cell lung cancer (mSCLC)) received 1 mg/kg magrolimab intravenously (IV) on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 113 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 113 weeks; each cycle length = 21 days.
OG001	Phase 2 Cohort 1a, mNSCLC (Magrolimab + Docetaxel)	Participants with mNSCLC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 90 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 69 weeks; each cycle length = 21 days.
OG002	Phase 2 Cohort 1b, mUC (Magrolimab + Docetaxel)

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Anaemia	Blood and lymphatic system disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0013 affected29 at risk EG0022 affected26 at risk EG0033 affected42 at risk
Febrile neutropenia	Blood and lymphatic system disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0013 affected29 at risk EG0024 affected26 at risk EG003
Neutropenia	Blood and lymphatic system disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0012 affected29 at risk EG0021 affected26 at risk EG003
Myocardial infarction	Cardiac disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Inappropriate antidiuretic hormone secretion	Endocrine disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Diarrhoea	Gastrointestinal disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0011 affected29 at risk EG0020 affected26 at risk EG003
Gastrointestinal haemorrhage	Gastrointestinal disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Neutropenic colitis	Gastrointestinal disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Rectal haemorrhage	Gastrointestinal disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0011 affected29 at risk EG0020 affected26 at risk EG003
Small intestinal haemorrhage	Gastrointestinal disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Fatigue	General disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0021 affected26 at risk EG003
Hyperthermia	General disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Bronchitis	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Clostridium difficile infection	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Encephalitis	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Kidney infection	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0021 affected26 at risk EG003
Lung abscess	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0011 affected29 at risk EG0020 affected26 at risk EG003
Neutropenic sepsis	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0021 affected26 at risk EG003
Pneumocystis jirovecii pneumonia	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Pneumonia	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0014 affected29 at risk EG0021 affected26 at risk EG003
Pneumonia viral	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Respiratory tract infection	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0011 affected29 at risk EG0021 affected26 at risk EG003
Sepsis	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0011 affected29 at risk EG0021 affected26 at risk EG003
Urinary tract infection	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0021 affected26 at risk EG003
Infusion related reaction	Injury, poisoning and procedural complications	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0011 affected29 at risk EG0020 affected26 at risk EG003
Transfusion reaction	Injury, poisoning and procedural complications	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0011 affected29 at risk EG0020 affected26 at risk EG003
Lymphocyte count decreased	Investigations	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Neutrophil count decreased	Investigations	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
White blood cell count decreased	Investigations	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Dehydration	Metabolism and nutrition disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0011 affected29 at risk EG0020 affected26 at risk EG003
Hyponatraemia	Metabolism and nutrition disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Back pain	Musculoskeletal and connective tissue disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0011 affected29 at risk EG0020 affected26 at risk EG003
Epilepsy	Nervous system disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0021 affected26 at risk EG003
Haemorrhage intracranial	Nervous system disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Neuritis	Nervous system disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Presyncope	Nervous system disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0011 affected29 at risk EG0020 affected26 at risk EG003
Seizure	Nervous system disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Chronic obstructive pulmonary disease	Respiratory, thoracic and mediastinal disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Dyspnoea	Respiratory, thoracic and mediastinal disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Haemoptysis	Respiratory, thoracic and mediastinal disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0011 affected29 at risk EG0020 affected26 at risk EG003
Lung disorder	Respiratory, thoracic and mediastinal disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Pleural effusion	Respiratory, thoracic and mediastinal disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0021 affected26 at risk EG003
Pneumonitis	Respiratory, thoracic and mediastinal disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0011 affected29 at risk EG0020 affected26 at risk EG003
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0022 affected26 at risk EG003
Pulmonary oedema	Respiratory, thoracic and mediastinal disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0011 affected29 at risk EG0020 affected26 at risk EG003
Respiratory distress	Respiratory, thoracic and mediastinal disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0011 affected29 at risk EG0020 affected26 at risk EG003
Deep vein thrombosis	Vascular disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0021 affected26 at risk EG003
Hypotension	Vascular disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0021 affected26 at risk EG003

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Anaemia	Blood and lymphatic system disorders	MedDRA 27.0	Systematic Assessment	EG0005 affected9 at risk EG00122 affected29 at risk EG00214 affected26 at risk EG00326 affected42 at risk
Febrile neutropenia	Blood and lymphatic system disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0012 affected29 at risk EG0020 affected26 at risk EG003
Leukocytosis	Blood and lymphatic system disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0022 affected26 at risk EG003
Leukopenia	Blood and lymphatic system disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0015 affected29 at risk EG0024 affected26 at risk EG003
Lymphopenia	Blood and lymphatic system disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0012 affected29 at risk EG0022 affected26 at risk EG003
Neutropenia	Blood and lymphatic system disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG00113 affected29 at risk EG00213 affected26 at risk EG003
Thrombocytopenia	Blood and lymphatic system disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0013 affected29 at risk EG0025 affected26 at risk EG003
Tachycardia	Cardiac disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Abdominal pain	Gastrointestinal disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0012 affected29 at risk EG0021 affected26 at risk EG003
Abdominal pain upper	Gastrointestinal disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0012 affected29 at risk EG0021 affected26 at risk EG003
Constipation	Gastrointestinal disorders	MedDRA 27.0	Systematic Assessment	EG0002 affected9 at risk EG0016 affected29 at risk EG0024 affected26 at risk EG003
Diarrhoea	Gastrointestinal disorders	MedDRA 27.0	Systematic Assessment	EG0002 affected9 at risk EG00114 affected29 at risk EG0026 affected26 at risk EG003
Dyspepsia	Gastrointestinal disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0022 affected26 at risk EG003
Dysphagia	Gastrointestinal disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Gastrooesophageal reflux disease	Gastrointestinal disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0011 affected29 at risk EG0021 affected26 at risk EG003
Nausea	Gastrointestinal disorders	MedDRA 27.0	Systematic Assessment	EG0003 affected9 at risk EG0015 affected29 at risk EG0024 affected26 at risk EG003
Stomatitis	Gastrointestinal disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0014 affected29 at risk EG0023 affected26 at risk EG003
Vomiting	Gastrointestinal disorders	MedDRA 27.0	Systematic Assessment	EG0002 affected9 at risk EG0014 affected29 at risk EG0024 affected26 at risk EG003
Asthenia	General disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG00118 affected29 at risk EG00210 affected26 at risk EG003
Chills	General disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0021 affected26 at risk EG003
Fatigue	General disorders	MedDRA 27.0	Systematic Assessment	EG0006 affected9 at risk EG0016 affected29 at risk EG0025 affected26 at risk EG003
Generalised oedema	General disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Influenza like illness	General disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0023 affected26 at risk EG003
Malaise	General disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Mucosal inflammation	General disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0022 affected26 at risk EG003
Non-cardiac chest pain	General disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Oedema peripheral	General disorders	MedDRA 27.0	Systematic Assessment	EG0003 affected9 at risk EG0016 affected29 at risk EG0025 affected26 at risk EG003
Pyrexia	General disorders	MedDRA 27.0	Systematic Assessment	EG0003 affected9 at risk EG00111 affected29 at risk EG0028 affected26 at risk EG003
Vascular device occlusion	General disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Contrast media reaction	Immune system disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Candida infection	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0011 affected29 at risk EG0021 affected26 at risk EG003
Covid-19	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0012 affected29 at risk EG0021 affected26 at risk EG003
Fungal infection	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Localised infection	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Nail infection	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Nasopharyngitis	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0012 affected29 at risk EG0020 affected26 at risk EG003
Oral candidiasis	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0002 affected9 at risk EG0010 affected29 at risk EG0021 affected26 at risk EG003
Osteomyelitis	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Respiratory tract infection	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0013 affected29 at risk EG0021 affected26 at risk EG003
Tooth abscess	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Upper respiratory tract infection	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0013 affected29 at risk EG0020 affected26 at risk EG003
Urinary tract infection	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0024 affected26 at risk EG003
Vulvovaginal candidiasis	Infections and infestations	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Infusion related reaction	Injury, poisoning and procedural complications	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0014 affected29 at risk EG0022 affected26 at risk EG003
Transfusion reaction	Injury, poisoning and procedural complications	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0012 affected29 at risk EG0020 affected26 at risk EG003
Alanine aminotransferase increased	Investigations	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0022 affected26 at risk EG003
Blood bilirubin increased	Investigations	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
C-reactive protein increased	Investigations	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0022 affected26 at risk EG003
Lymphocyte count decreased	Investigations	MedDRA 27.0	Systematic Assessment	EG0002 affected9 at risk EG0013 affected29 at risk EG0020 affected26 at risk EG003
Neutrophil count decreased	Investigations	MedDRA 27.0	Systematic Assessment	EG0003 affected9 at risk EG0014 affected29 at risk EG0020 affected26 at risk EG003
Sars-cov-2 test positive	Investigations	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Weight decreased	Investigations	MedDRA 27.0	Systematic Assessment	EG0002 affected9 at risk EG0011 affected29 at risk EG0022 affected26 at risk EG003
White blood cell count decreased	Investigations	MedDRA 27.0	Systematic Assessment	EG0002 affected9 at risk EG0012 affected29 at risk EG0020 affected26 at risk EG003
Decreased appetite	Metabolism and nutrition disorders	MedDRA 27.0	Systematic Assessment	EG0002 affected9 at risk EG0017 affected29 at risk EG0022 affected26 at risk EG003
Dehydration	Metabolism and nutrition disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0011 affected29 at risk EG0020 affected26 at risk EG003
Hyperglycaemia	Metabolism and nutrition disorders	MedDRA 27.0	Systematic Assessment	EG0002 affected9 at risk EG0011 affected29 at risk EG0020 affected26 at risk EG003
Hypoalbuminaemia	Metabolism and nutrition disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0012 affected29 at risk EG0022 affected26 at risk EG003
Hypocalcaemia	Metabolism and nutrition disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0021 affected26 at risk EG003
Hypoglycaemia	Metabolism and nutrition disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Hypokalaemia	Metabolism and nutrition disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0015 affected29 at risk EG0020 affected26 at risk EG003
Hyponatraemia	Metabolism and nutrition disorders	MedDRA 27.0	Systematic Assessment	EG0002 affected9 at risk EG0015 affected29 at risk EG0021 affected26 at risk EG003
Hypophosphataemia	Metabolism and nutrition disorders	MedDRA 27.0	Systematic Assessment	EG0002 affected9 at risk EG0011 affected29 at risk EG0023 affected26 at risk EG003
Iron overload	Metabolism and nutrition disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Arthralgia	Musculoskeletal and connective tissue disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0016 affected29 at risk EG0024 affected26 at risk EG003
Back pain	Musculoskeletal and connective tissue disorders	MedDRA 27.0	Systematic Assessment	EG0002 affected9 at risk EG0012 affected29 at risk EG0022 affected26 at risk EG003
Bone pain	Musculoskeletal and connective tissue disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0021 affected26 at risk EG003
Flank pain	Musculoskeletal and connective tissue disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0023 affected26 at risk EG003
Muscular weakness	Musculoskeletal and connective tissue disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0011 affected29 at risk EG0020 affected26 at risk EG003
Musculoskeletal chest pain	Musculoskeletal and connective tissue disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0015 affected29 at risk EG0021 affected26 at risk EG003
Myalgia	Musculoskeletal and connective tissue disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0011 affected29 at risk EG0023 affected26 at risk EG003
Pain in extremity	Musculoskeletal and connective tissue disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0012 affected29 at risk EG0021 affected26 at risk EG003
Cerebral small vessel ischaemic disease	Nervous system disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Dizziness	Nervous system disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0011 affected29 at risk EG0021 affected26 at risk EG003
Dysgeusia	Nervous system disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0012 affected29 at risk EG0022 affected26 at risk EG003
Headache	Nervous system disorders	MedDRA 27.0	Systematic Assessment	EG0002 affected9 at risk EG0011 affected29 at risk EG0022 affected26 at risk EG003
Lethargy	Nervous system disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Migraine	Nervous system disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Neurotoxicity	Nervous system disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0016 affected29 at risk EG0021 affected26 at risk EG003
Peripheral sensory neuropathy	Nervous system disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0011 affected29 at risk EG0020 affected26 at risk EG003
Anxiety	Psychiatric disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0021 affected26 at risk EG003
Confusional state	Psychiatric disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Depression	Psychiatric disorders	MedDRA 27.0	Systematic Assessment	EG0003 affected9 at risk EG0012 affected29 at risk EG0020 affected26 at risk EG003
Insomnia	Psychiatric disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0012 affected29 at risk EG0022 affected26 at risk EG003
Cystitis noninfective	Renal and urinary disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Dysuria	Renal and urinary disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0022 affected26 at risk EG003
Pollakiuria	Renal and urinary disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0021 affected26 at risk EG003
Urinary incontinence	Renal and urinary disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Urinary retention	Renal and urinary disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0011 affected29 at risk EG0020 affected26 at risk EG003
Vulvovaginal pruritus	Reproductive system and breast disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Cough	Respiratory, thoracic and mediastinal disorders	MedDRA 27.0	Systematic Assessment	EG0002 affected9 at risk EG0014 affected29 at risk EG0022 affected26 at risk EG003
Dysphonia	Respiratory, thoracic and mediastinal disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Dyspnoea	Respiratory, thoracic and mediastinal disorders	MedDRA 27.0	Systematic Assessment	EG0002 affected9 at risk EG0019 affected29 at risk EG0023 affected26 at risk EG003
Haemoptysis	Respiratory, thoracic and mediastinal disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0011 affected29 at risk EG0021 affected26 at risk EG003
Hiccups	Respiratory, thoracic and mediastinal disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0010 affected29 at risk EG0022 affected26 at risk EG003
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0012 affected29 at risk EG0020 affected26 at risk EG003
Rhinorrhoea	Respiratory, thoracic and mediastinal disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Sneezing	Respiratory, thoracic and mediastinal disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Alopecia	Skin and subcutaneous tissue disorders	MedDRA 27.0	Systematic Assessment	EG0002 affected9 at risk EG0018 affected29 at risk EG0026 affected26 at risk EG003
Nail discolouration	Skin and subcutaneous tissue disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Nail disorder	Skin and subcutaneous tissue disorders	MedDRA 27.0	Systematic Assessment	EG0000 affected9 at risk EG0012 affected29 at risk EG0021 affected26 at risk EG003
Palmar-plantar erythrodysaesthesia syndrome	Skin and subcutaneous tissue disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Pruritus	Skin and subcutaneous tissue disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0014 affected29 at risk EG0021 affected26 at risk EG003
Rash	Skin and subcutaneous tissue disorders	MedDRA 27.0	Systematic Assessment	EG0002 affected9 at risk EG0012 affected29 at risk EG0022 affected26 at risk EG003
Hypotension	Vascular disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0013 affected29 at risk EG0020 affected26 at risk EG003
Hypovolaemic shock	Vascular disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003
Superficial vein thrombosis	Vascular disorders	MedDRA 27.0	Systematic Assessment	EG0001 affected9 at risk EG0010 affected29 at risk EG0020 affected26 at risk EG003

PubMed Identifier	Type	Citation	Retractions
	Background	Van Burren N, U'Ren L, Song K, Liu Y, Correa P, Tang S, et al. Biomarker analysis of magrolimab plus docetaxel in patients with 2L+ mNSCLC from ELEVATE Lung and UC, a Phase 2 multicohort study [Abstract]. J Immunother Cancer. 2024;12. doi:10.1136/jitc- 2024-SITC2024.0184.
	Background	Van Burren N, U'Ren L, Song K, Liu Y, Correa P, Tang S, et al. Biomarker analysis of magrolimab plus docetaxel in patients with 2L+ mNSCLC from ELEVATE Lung and UC, a Phase 2 multicohort study. Poster presented at: 2024 Society for Immunotherapy of Cancer (SITC); 2024 Nov 6-10; Houston, TX, USA.
	Background	Juan-Vidal O, Fang B, Paz-Ares LG, Ortega Granado AL, Vicuna BD, Bodnar L, et al. Magrolimab + docetaxel in previously treated patients with metastatic non-small cell lung cancer [Abstract]. J Immunother Cancer. 2024;12. doi:10.1136/jitc-2024-SITC2024.0604.
	Background	Juan-Vidal O, Fang B, Paz-Ares LG, Ortega Granado AL, Vicuna BD, Bodnar L, et al. Magrolimab + docetaxel in previously treated patients with metastatic non-small cell lung cancer. Poster presented at: 2024 Society for Immunotherapy of Cancer (SITC); 2024 Nov 6-10; Houston, TX, USA.
	Background	Vaishampayan UN, Puri S, Kummar S, Perez JM, Italiano A, Shao J, et al. A Phase 2 multiarm study of magrolimab in combination with docetaxel in patients with locally advanced or metastatic solid tumors: ELEVATE-Lung and UC. J Clin Oncol. 2023;41(16_suppl):TPS9142-TPS9142.

ID	Term
D043823	Taxoids
D043822	Cyclodecanes
D003516	Cycloparaffins
D006840	Hydrocarbons, Alicyclic
D006844	Hydrocarbons, Cyclic
D006838	Hydrocarbons
D009930	Organic Chemicals
D004224	Diterpenes
D013729	Terpenes

ID	Title	Description
BG000	Safety Run-in Cohort 1 (Magrolimab + Docetaxel)	Participants with solid tumors (including metastatic non small cell lung cancer (mNSCLC), metastatic urothelial cancer (mUC), and metastatic small cell lung cancer (mSCLC)) received 1 mg/kg magrolimab intravenously (IV) on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 113 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 113 weeks; each cycle length = 21 days.
BG001	Phase 2 Cohort 1a, mNSCLC (Magrolimab + Docetaxel)	Participants with mNSCLC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 90 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 69 weeks; each cycle length = 21 days.
BG002	Phase 2 Cohort 1b, mUC (Magrolimab + Docetaxel)	Participants with mUC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 68 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 68 weeks; each cycle length = 21 days.
BG003	Phase 2 Cohort 1c, mSCLC (Magrolimab + Docetaxel)	Participants with mSCLC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 72 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 72 weeks; each cycle length = 21 days.
BG004	Total~(N=106)

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Safety Run-in Cohort 1 (Magrolimab + Docetaxel)	Participants with solid tumors (including metastatic non small cell lung cancer (mNSCLC), metastatic urothelial cancer (mUC), and metastatic small cell lung cancer (mSCLC)) received 1 mg/kg magrolimab intravenously (IV) on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 113 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 113 weeks; each cycle length = 21 days.	6	9	5	9	9	9
EG001	Phase 2 Cohort 1a, mNSCLC (Magrolimab + Docetaxel)	Participants with mNSCLC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 90 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 69 weeks; each cycle length = 21 days.	17	29	16	29	29	29
EG002	Phase 2 Cohort 1b, mUC (Magrolimab + Docetaxel)	Participants with mUC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 68 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 68 weeks; each cycle length = 21 days.	18	26	12	26	26	26
EG003	Phase 2 Cohort 1c, mSCLC (Magrolimab + Docetaxel)	Participants with mSCLC received 1 mg/kg magrolimab IV on Day 1, 30 mg/kg IV on Days 8 and 15 of cycle 1; 30 mg/kg IV on Days 1, 8 and 15 of Cycle 2; 60 mg/kg IV on Day 1 of Cycle 3 and onwards for up to 72 weeks; and 75 mg/m^2 docetaxel IV on Day 1 of each cycle for up to 72 weeks; each cycle length = 21 days.	37	42	18	42	41	42